BPC-157 + TB-500
Pre-mixed research combination of BPC-157 (synthetic pentadecapeptide, GEPPPGKPADDAGLV) and TB-500 (Thymosin Beta-4 active fragment, Ac-LKKTETQ). Studied in preclinical models for multi-pathway tissue repair signalling, angiogenic modulation, and cytoskeletal remodelling via complementary mechanisms.
Mechanism of Action
BPC-157 (Body Protection Compound) is a synthetic 15-amino-acid peptide with the sequence GEPPPGKPADDAGLV, derived as a partial fragment of a larger compound originally identified in human gastric juice. Its most consistently reported mechanistic effect is angiogenic signalling: published in vitro and in vivo work has described upregulation of vascular endothelial growth factor receptor 2 (VEGFR-2), enhanced endothelial cell migration, and accelerated vascularisation of injured tissue in rodent models. Additional mechanistic axes include interaction with the nitric oxide system, modulation of growth hormone receptor expression in tendon fibroblasts, and gastroprotective activity across diverse mucosal injury models.
TB-500 is a synthetic fragment corresponding to the active region (residues 17–23, sequence Ac-LKKTETQ) of Thymosin Beta-4, an endogenous G-actin-sequestering protein. The primary mechanistic effect studied in published research is regulation of G-actin availability: by sequestering monomeric actin, TB-500 reduces its incorporation into cytoskeletal filaments, modulating cell motility and migration dynamics. This mechanism has been associated in published preclinical work with enhanced migration of endothelial cells, keratinocytes, and myoblasts, contributing to angiogenesis, epithelial repair, and satellite cell activation in muscle tissue.
The mechanistic rationale for the combination rests on the partial complementarity of these two pathways. BPC-157 acts primarily on extracellular signalling cascades (VEGFR-2, NO, GH receptor) while TB-500 acts on intracellular cytoskeletal dynamics (G-actin sequestration). Both have been independently associated with angiogenic promotion, which may represent a point of convergent or additive activity. Researchers investigating multi-pathway tissue repair models may use the pre-mixed combination to probe whether co-administration of these mechanistically distinct agents produces additive or independent effects compared with either compound alone.
Key Research Findings
- BPC-157 alone has demonstrated accelerated healing of transected skeletal muscle with restoration of biomechanical function in rat models, providing a baseline for comparison in multi-compound repair studies. Staresinic et al., Journal of Orthopaedic Research, 2006.
- Thymosin Beta-4 (parent protein of TB-500) was identified as the primary actin-sequestering protein in platelets, with subsequent work establishing its role in regulation of cell migration and wound healing across multiple cell types. Safer et al., Journal of Biological Chemistry, 1991.
- The seven-amino-acid actin-binding motif of Thymosin Beta-4 (LKKTETQ, the active sequence of TB-500) has been shown to be essential for the parent protein’s angiogenic activity, reproducing its endothelial cell migration and vessel-sprouting effects at near-identical potency in preclinical assays. Philp et al., FASEB Journal, 2003.
- BPC-157 has been associated with upregulation of VEGFR-2 and enhanced tube formation in endothelial cell culture, providing a vascular mechanism complementary to TB-500’s cell migration effects. Sikiric research group, University of Zagreb, BPC-157 angiogenesis literature.
- Combination approaches using both angiogenic signalling peptides and cytoskeletal modulators have been explored in tissue engineering literature as a strategy for addressing both vascularity and cellular organisation in repair models. Tissue engineering and regenerative medicine combination-peptide literature, 2010s.
Citations last reviewed: 1 October 2026
As Supplied by BasedPeps
Researcher FAQ
What is the BPC-157 + TB-500 combination?
A pre-mixed, co-lyophilised research blend containing BPC-157 (synthetic pentadecapeptide, GEPPPGKPADDAGLV) and TB-500 (Thymosin Beta-4 active fragment, Ac-LKKTETQ) in equal amounts per vial. The two peptides have distinct primary mechanisms — angiogenic signalling and NO modulation for BPC-157, actin sequestration and cell migration modulation for TB-500 — and are investigated together for multi-pathway tissue repair research.
How is the blend reconstituted for laboratory use?
Reconstitute in sterile bacteriostatic water or 0.9% sodium chloride, gently swirling (not shaking) until fully dissolved. Both peptides are co-lyophilised in the same vial, so a single reconstitution step yields a solution containing both compounds. Store reconstituted solution at 2–8 °C and use within 28 days. Minimise freeze-thaw cycles.
Do the two peptides interfere with each other in solution?
No incompatibility has been reported in the published literature between BPC-157 and Thymosin Beta-4 / TB-500 in solution. The two peptides have different sequences, molecular weights, and target pathways. Co-lyophilisation is standard for multi-component research peptide blends and is used commercially for this combination.
Is a Certificate of Analysis provided for both components?
Yes. Every BasedPeps BPC-157 + TB-500 lot includes a third-party Certificate of Analysis documenting HPLC purity (≥99%) for each peptide component individually, plus mass spectrometric identity confirmation for both. Certificates of Analysis are available per batch on request.
Can the individual compounds be ordered separately?
BPC-157 is available as an individual product. TB-500 (Thymosin β4) is currently supplied only within this BPC-157 + TB-500 combination vial, offered for researchers who require both simultaneously in a single reconstitution.
View BasedPeps BPC-157 + TB-500
Research-grade co-lyophilised combination. Third-party HPLC and mass spectrometry verification per lot for each component. Certificate of Analysis available on request. Dispatched from Riga, Latvia within 24 hours.
View BasedPeps BPC-157 + TB-500 →